This activity focuses on the prescription of aducanumab, a groundbreaking amyloid ß-directed monoclonal antibody for the treatment of Alzheimer disease (AD). Granted accelerated approval by the United States Food and Drug Administration (FDA) in June 2021, aducanumab is the first AD treatment to receive formal regulatory clearance since 2003. The approval was based on clinical trial data demonstrating a reduction in amyloid plaques in treated individuals. This educational activity discusses key aspects such as indications, patient selection strategies, the mechanism of action, adverse event profiles, mandatory monitoring protocols, and contraindications for aducanumab use in AD management. The course emphasizes the pivotal role of interdisciplinary care teams in navigating these factors to deliver comprehensive care to individuals with AD, underlining the significance of close monitoring for potential adverse effects, notably amyloid-related imaging abnormalities (ARIA), which may necessitate dosing interruptions.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/137525
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: All Practice Areas (e.g. ethics), General Surgery, Geriatric Medicine, Internal Medicine, Neurocritical Care